Autopsy report · NCT01878786
A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys
Cause of deathSafety
“Interim results suggested a concern for patient outcomes and safety”
Life of this trial
- Ran for about 4 years 6 months before it stopped.
- 25 participants enrolled.
- Results were posted on the registry 1 year 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Matthew Cooper
- Sponsor type
- University, hospital or other
- Conditions
- Delayed Graft Function
- Interventions
- Everolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
- Participants
- 25
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
“Interim analysis indicated low probability of clinically significant result” - In-exsufflator Cough Assist Device in Patients With Symptomatic Bronchiectasis
“interim analysis indicates statistical futility for primary outcomes” - Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma
“we collected data of a total of 19 patients for an interim analysis. but there are less than 7 responses out of the initial 19 patients.” - Atrial Pressure Electrophysiology Pilot Study
“Interim evaluation of data after internal safety report from sponsor.” - A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
“Interim assessment: Lack of efficacy”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.